Abstract:Abstract In 1806, French physician Baron Jean-Louis Alibert treated a 56-year-old man with a desquamating rash and skin tumours. Alibert considered this to be a variant of yaws. In 1829 Alibert named the condition mycosis fungoides (MF), meaning ‘mushroom-like fungal disease’. Over 100 years later, French dermatologist Albert Sézary published papers from 1938 to 1949 detailing a mysterious disease that caused erythroderma and ‘cellules monstrueuses’, describing cutaneous ‘monster cells’. In 1961, these clinical findings were collated together into ‘Sézary syndrome’. Over this time there was widespread confusion between these conditions, fungal infections and yaws. In the 1870s English dermatologist William Tilbury Fox published a dermatology atlas detailing cases similar to what we know now as MF, with the name ‘fibroma fungoides’. The atlas described MF as a type of fungus, before giving a description of yaws and painting a clinical picture that differed from that of a lymphoma. In 1975, Pierre-Antoine-Ernest Bazin and associates in suggested the classification system and term we now recognize as cutaneous T-cell lymphoma (CTCL). Neoplastic cells have been thought to arise from chronic activation of T cells via antigen-presenting cells, yet the antigen to trigger this response remains unknown. Several potential bacterial, viral, fungal and iatrogenic causes have been studied, but no reliable triggers have been discovered. In 2018, the World Health Organization and European Organisation for Research and Treatment of Cancer officially recognized four types of MF. These are the classic Alibert–Bazin type (representing 88.6% of cases) and its three subtypes; folliculotropic MF (11.4%), Pagetoid reticulosis, and granulomatous slack skin (both with a combined 1% prevalence). CTCL has an incidence of approximately 0.2–0.6 per 100 000 person-years, with MF being the most common subtype. MF is twice as common in male as in female patients. It is twice as common in those of Black ethnic background than in White and Asian ethnicities. Development of immunohistochemistry and polymerase chain reaction for the T-cell receptor gene in the 1980s improved the diagnosis of CTCL. However, diagnosis of MF remains challenging due to its heterogeneous presentation, often mimicking inflammatory dermatoses. Advanced disease therapies have evolved from cytotoxic chemotherapy in the 1970s to novel monoclonal antibodies such as mogamulizumab, targeting proteins on T-cell lymphoma cells (CCR4). Reflection on the past two centuries from Alibert to mogamulizumab offers insight into the challenges that accompany the aetiology, diagnosis, classification and management of MF.

A Comprehensive Study on Aberrant CD20-Positive Mycosis Fungoides: Clinical and Prognostic Insights

Unveiling the Rarity: CD20 Expression in Mycosis Fungoides and Its Clinical Significance

Clinical Features, Tumor Biology, and Prognosis Associated with MYC Rearrangement and Myc Overexpression in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-Chop

Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides

Null T‐cell phenotype mycosis fungoides with aberrant CD20 and CD56 expression: A diagnostic dilemma

Evaluation of the prognostic significance of clinical features of tumoral lesions in an extensive series of mycosis fungoides

A retrospective study of prognostic factors and treatment outcome in advanced-stage Mycosis Fungoides and Sezary Syndrome

Genomic profiling of Mycosis Fungoides identifies patients at high risk of disease progression

P068 A history of mycosis fungoides: from Alibert to mogamulizumab

H03 (P068) A history of mycosis fungoides: from Alibert to mogamulizumab

Prognostic Factors and Survival Outcomes among Patients with Mycosis Fungoides in China: A 12-Year Review.

Mycosis fungoides: Current trends in diagnosis and management

A Man with Worsening Scaling Plaques and a New Onset Large Draining Ulcerated Tumor

Proteomic Screening and Verification of Biomarkers in Different Stages of Mycosis Fungoides: A pilot Study

The Role of microRNA in Pathogenesis, Diagnosis, Different Variants, Treatment and Prognosis of Mycosis Fungoides

[Translated article] Survival Analysis and Prognostic Factors in a Case Series of 148 Cutaneous T-Cell Lymphomas

Prognostic Factors and Survival Outcomes Among Patients With Mycosis Fungoides in China

On the Way to Curing Advanced-Stage Mycosis Fungoides/Sézary Syndrome

Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma

When mycosis fungoides seems not to be within the spectrum of clinical and histopathological differential diagnoses

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma